120 related articles for article (PubMed ID: 30169461)
1. Current management of patients with chronic myelomonocytic leukemia.
Mora E; Sanz GF
Curr Opin Oncol; 2018 Nov; 30(6):409-417. PubMed ID: 30169461
[TBL] [Abstract][Full Text] [Related]
2. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.
Patnaik MM; Tefferi A
Am J Hematol; 2024 Jun; 99(6):1142-1165. PubMed ID: 38450850
[TBL] [Abstract][Full Text] [Related]
3. Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification.
Mosquera Orgueira A; Perez Encinas MM; Diaz Varela N; Wang YH; Mora E; Diaz-Beya M; Montoro MJ; Pomares Marin H; Ramos Ortega F; Tormo M; Jerez A; Nomdedeu J; de Miguel Sanchez C; Arenillas L; Carcel P; Cedena Romero MT; Xicoy Cirici B; Rivero Arango E; Del Orbe Barreto RA; Benlloch L; Lin CC; Tien HF; Pérez Míguez C; Crucitti D; Díez Campelo M; Valcárcel D
Br J Haematol; 2024 Apr; 204(4):1529-1535. PubMed ID: 38411250
[TBL] [Abstract][Full Text] [Related]
4. Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy.
Schnegg-Kaufmann AS; Thoms JAI; Bhuyan GS; Hampton HR; Vaughan L; Rutherford K; Kakadia PM; Lee HM; Johansson EMV; Failes TW; Arndt GM; Koval J; Lindeman R; Warburton P; Rodriguez-Meira A; Mead AJ; Unnikrishnan A; Davidson S; Polizzotto MN; Hertzberg M; Papaemmanuil E; Bohlander SK; Faridani OR; Jolly CJ; Zanini F; Pimanda JE
Blood; 2023 Mar; 141(11):1316-1321. PubMed ID: 36493342
[TBL] [Abstract][Full Text] [Related]
5. Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022.
Baumgartner F; Baer C; Bamopoulos S; Ayoub E; Truger M; Meggendorfer M; Lenk M; Hoermann G; Hutter S; Müller H; Walter W; Müller ML; Nadarajah N; Blombery P; Keller U; Kern W; Haferlach C; Haferlach T
Blood; 2024 Mar; 143(12):1139-1156. PubMed ID: 38064663
[TBL] [Abstract][Full Text] [Related]
6. Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
Montalban-Bravo G; Jabbour E; Borthakur G; Kadia T; Ravandi F; Chien K; Pemmaraju N; Hammond D; Dong XQ; Huang X; Schneider H; John R; Kanagal-Shamana R; Loghavi S; Kantarjian H; Garcia-Manero G
Br J Haematol; 2024 Mar; 204(3):898-909. PubMed ID: 37946611
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of intermediate or high-risk CMML patients treated with hypomethylating agents combined with venetoclax: A single center experience.
Li C; Deng C; Wu P; Liu K; Huang X; Li M; Chen X; Geng S; Lai P; Weng J; Du X
Clin Transl Sci; 2024 Jan; 17(1):e13711. PubMed ID: 38129985
[TBL] [Abstract][Full Text] [Related]
8. A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation.
Gagelmann N; Badbaran A; Beelen DW; Salit RB; Stölzel F; Rautenberg C; Becker H; Radujkovic A; Panagiota V; Bogdanov R; Christopeit M; Park Y; Nibourel O; Luft T; Koldehoff M; Corsten M; Heuser M; Finke J; Kobbe G; Platzbecker U; Robin M; Scott BL; Kröger N
Blood Adv; 2021 Mar; 5(6):1760-1769. PubMed ID: 33755092
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of molecular markers in chronic myelomonocytic leukemia: a disease associated with several gene alterations.
Bastie JN; Aucagne R; Droin N; Solary E; Delva L
Cell Mol Life Sci; 2012 Sep; 69(17):2853-61. PubMed ID: 22415325
[TBL] [Abstract][Full Text] [Related]
10. Spontaneous remission of choroidal involvement by chronic myelomonocytic leukemia: a case report.
Diral E; Catalano G; Cicinelli MV; Distefano A; Mastaglio S; Vago L; Lupo Stanghellini MT; Bernardi M; Ponzoni M; Ciceri F; Carrabba MG
Front Oncol; 2024; 14():1399894. PubMed ID: 38756666
[TBL] [Abstract][Full Text] [Related]
11. Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia.
Montalban-Bravo G; Thongon N; Rodriguez-Sevilla JJ; Ma F; Ganan-Gomez I; Yang H; Kim YJ; Adema V; Wildeman B; Tanaka T; Darbaniyan F; Al-Atrash G; Dwyer K; Loghavi S; Kanagal-Shamanna R; Song X; Zhang J; Takahashi K; Kantarjian H; Garcia-Manero G; Colla S
Cell Rep Med; 2024 May; ():101585. PubMed ID: 38781960
[TBL] [Abstract][Full Text] [Related]
12. Robin M, de Wreede LC, Padron E, et al. Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis. Blood. 2022;140(12):1408-1418.
Blood; 2023 Jun; 141(26):3232-3233. PubMed ID: 37383000
[No Abstract] [Full Text] [Related]
13. Cabot rings in chronic myelomonocytic leukemia.
Strasser B; Haushofer A
Blood; 2023 Nov; 142(20):1757. PubMed ID: 37971756
[No Abstract] [Full Text] [Related]
14. Recent Updates on Chronic Myelomonocytic Leukemia.
Loghavi S; Khoury JD
Curr Hematol Malig Rep; 2018 Dec; 13(6):446-454. PubMed ID: 30311069
[TBL] [Abstract][Full Text] [Related]
15. Chronic Myelomonocytic Leukemia: 2018 Update to Prognosis and Treatment.
Elmariah H; DeZern AE
Curr Hematol Malig Rep; 2019 Jun; 14(3):154-163. PubMed ID: 31093889
[TBL] [Abstract][Full Text] [Related]
16. Mutation Clearance after Transplantation for Myelodysplastic Syndrome.
Duncavage EJ; Jacoby MA; Chang GS; Miller CA; Edwin N; Shao J; Elliott K; Robinson J; Abel H; Fulton RS; Fronick CC; O'Laughlin M; Heath SE; Brendel K; Saba R; Wartman LD; Christopher MJ; Pusic I; Welch JS; Uy GL; Link DC; DiPersio JF; Westervelt P; Ley TJ; Trinkaus K; Graubert TA; Walter MJ
N Engl J Med; 2018 Sep; 379(11):1028-1041. PubMed ID: 30207916
[TBL] [Abstract][Full Text] [Related]
17. How I investigate chronic myelomonocytic leukemia.
Sangiorgio VFI; Arber DA; Orazi A
Int J Lab Hematol; 2020 Apr; 42(2):101-108. PubMed ID: 31841277
[TBL] [Abstract][Full Text] [Related]
18. Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment.
Coltro G; Patnaik MM
Curr Oncol Rep; 2019 Nov; 21(11):101. PubMed ID: 31728739
[TBL] [Abstract][Full Text] [Related]
19. Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions.
Valent P; Orazi A; Savona MR; Patnaik MM; Onida F; van de Loosdrecht AA; Haase D; Haferlach T; Elena C; Pleyer L; Kern W; Pemovska T; Vladimer GI; Schanz J; Keller A; Lübbert M; Lion T; Sotlar K; Reiter A; De Witte T; Pfeilstöcker M; Geissler K; Padron E; Deininger M; Orfao A; Horny HP; Greenberg PL; Arber DA; Malcovati L; Bennett JM
Haematologica; 2019 Oct; 104(10):1935-1949. PubMed ID: 31048353
[TBL] [Abstract][Full Text] [Related]
20. Oligo-monocytic CMML and other pre-CMML states: Clinical impact, prognostication and management.
Valent P
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101137. PubMed ID: 32460976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
